Bank of New York Mellon Corp raised its stake in shares of Mirati Therapeutics, Inc. (NASDAQ:MRTX) by 22.9% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 63,004 shares of the biotechnology company’s stock after buying an additional 11,753 shares during the period. Bank of New York Mellon Corp owned approximately 0.25% of Mirati Therapeutics worth $328,000 as of its most recent SEC filing.

Shares of Mirati Therapeutics, Inc. (MRTX) traded up 10.89% during trading on Friday, reaching $5.60. 441,321 shares of the company traded hands. The firm’s market capitalization is $139.83 million. Mirati Therapeutics, Inc. has a 12 month low of $2.70 and a 12 month high of $7.22. The firm has a 50-day moving average price of $4.50 and a 200-day moving average price of $4.51.

WARNING: “Mirati Therapeutics, Inc. (MRTX) Position Boosted by Bank of New York Mellon Corp” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/08/19/bank-of-new-york-mellon-corp-acquires-11753-shares-of-mirati-therapeutics-inc-mrtx-updated.html.

Several brokerages have issued reports on MRTX. Jefferies Group LLC set a $5.00 price target on shares of Mirati Therapeutics and gave the company a “hold” rating in a report on Friday, August 4th. ValuEngine downgraded shares of Mirati Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. Finally, Zacks Investment Research raised shares of Mirati Therapeutics from a “hold” rating to a “buy” rating and set a $4.75 price objective for the company in a research report on Wednesday, May 3rd. One research analyst has rated the stock with a sell rating, five have issued a hold rating and two have given a buy rating to the company’s stock. Mirati Therapeutics has a consensus rating of “Hold” and an average target price of $7.63.

Institutional Ownership by Quarter for Mirati Therapeutics (NASDAQ:MRTX)

Receive News & Stock Ratings for Mirati Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics Inc. and related stocks with our FREE daily email newsletter.